Match Document Document Title
10245312 Influenza virus reassortment  
New influenza donor strains for the production of reassortant influenza A viruses are provided.
US20190094227 DISEASE-ASSOCIATED ANTIGENS AND METHODS OF USE THEREOF  
The present disclosure provides synthetic antibodies specific for a disease-associated antigen, and methods of using the antibodies in disease therapy. The present disclosure further provides...
US20190091329 CATIONIC OIL-IN-WATER EMULSIONS  
This invention generally relates to cationic oil-in-water emulsions that contain high concentrations of cationic lipids and have a defined oil:lipid ratio. The cationic lipid can interact with the...
10238739 Manufacture of surfactant-containing compositions with enhanced stability  
Improved methods for the manufacture of pharmaceutical compositions comprising at least one surfactant, involving prefiltration of the surfactant prior to formulation into final products.
10238733 Cationic oil-in-water emulsions  
This invention generally relates to cationic oil-in-water emulsions that can be used to deliver negatively charged molecules, such as an RNA molecule. The emulsion particles comprise an oil core...
US20190083397 OIL-IN-WATER EMULSIONS INCLUDING RETINOIC ACID  
Retinoic acid, or an analogue thereof, is delivered within an oil-in-water emulsion to provide an improved immunological adjuvant.
10233429 Hand, foot, and mouth vaccines and methods of manufacture and use thereof  
The present disclosure relates to hand, foot, and mouth disease vaccines and immunogenic compositions having one or more antigens from at least one virus that causes hand, foot, and mouth disease...
10232031 Influenza virus reassortment  
New influenza donor strains for the production of reassortant influenza B viruses are provided.
US20190078093 OLIGONUCLEOTIDE PROBES AND USES THEREOF  
Methods and compositions are provided to identify oligonucleotides that bind targets of interest. The targets include tissues, cells, circulating biomarkers such as microvesicles, including those...
10226525 Group B Streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof  
The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS),...
US20190070282 IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS, KITS COMPRISING THE SAME AND USES THEREOF  
The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic...
US20190060437 MENINGOCOCCUS SEROGROUP X CONJUGATE  
The invention provides a conjugate of a Neisseria meningitidis serogroup X capsular polysaccharide and a carrier molecule. The conjugate is typically made by (a) oxidising a primary hydroxyl group...
10213383 Hydrophilic filtration during manufacture of vaccine adjuvants  
An improved method for the manufacture of an oil-in-water emulsion involves three procedures: (i) preparation of a preliminary emulsion; (ii) micro fluidization of the preliminary emulsion to...
US20190054189 RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES  
The present invention relates to RNA containing compositions for use in the treatment or prophylaxis of tumor and/or cancer diseases, to a pharmaceutical composition, to a kit and to uses of the...
US20190054164 VACCINATION IN NEWBORNS AND INFANTS  
The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age...
US20190054163 NOVEL INFLUENZA ANTIGENS  
The present invention relates to novel influenza antigens, novel immunogenic or vaccine compositions, as well as to uses of and to methods for producing said antigens and compositions. In...
US20190054162 INFLUENZA VACCINE  
The present invention relates to monovalent influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in...
US20190046635 COMPOSITION FOR IMMUNITY INDUCTION PROMOTION AND VACCINE PHARMACEUTICAL COMPOSITION  
The present invention aims to provide a composition for immunity induction promotion and a vaccine pharmaceutical composition each universally usable for induction of cellular immunity and/or...
10201608 Polynucleotides encoding humanized anti-CD40 antibodies  
The present disclosure relates to anti-CD40 antibodies, such as humanized anti-CD40 antibodies, that may be used in various therapeutic, prophylactic and diagnostic methods. The antibodies...
US20190040378 NOVEL NUCLEIC ACID MOLECULES  
The present invention provides novel artificial nucleic acid molecules encoding at least one antigenic peptide or protein and at least one additional sequence preferably targeting the antigenic...
10196429 Neisseria meningitidis composition and methods thereof  
In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B subfamily A A12 polypeptide. In another aspect, the invention relates to an...
10195264 Immunising against meningococcal serogroup Y using proteins  
The invention uses polypeptide antigens and/or OMVs to immunize against serogroups A, C, W135 and Y (and against serogroup Y in particular). Serogroup B polypeptides can achieve this protection,...
10195263 Compositions for immunising against Staphylococcus aureus  
An effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens are identified for use in immunisation. These polypeptides...
US20190032077 ARTIFICIAL NUCLEIC ACID MOLECULES  
The invention relates to an artificial nucleic acid molecule comprising at least one open reading frame and at least one 3′-untranslated region element (3′-UTR) element comprising a nucleic acid...
US20190031724 PAPILLOMAVIRUS CHIMERIC PROTEIN AND APPLICATION THEREOF  
Provided is a papillomavirus chimeric protein, the skeleton thereof being a papillomavirus L1 protein or a mutant thereof, at least one human papillomavirus 33-type L2 protein or mutant...
US20190030159 COMPOSITIONS OF VACCINES AND ADJUVANTS AND METHODS FOR THE TREATMENT OF URINARY TRACT INFECTIONS  
This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37° C. that can be produced at remarkably...
10188719 Conjugation of Streptococcal capsular saccharides  
Three conjugation methods for use with the capsular saccharide of Streptococcus agalactiae. In the first method, reductive amination of oxidized sialic acid residue side chains is used, but the...
US20190023746 NOROVIRUS DERIVED IMMUNOGENIC COMPOSITIONS AND METHODS  
The invention relates to chimeric norovirus VP1 proteins containing the S-domain of VP1 of a first norovirus strain and a P-domain that contains at least a portion of the P-domain of VP1 of a...
10183074 Cationic oil-in-water emulsions  
This invention generally relates to cationic oil-in-water emulsions that contain high concentrations of cationic lipids and have a defined oil:lipid ratio. The cationic lipid can interact with the...
US20190015501 NUCLEIC ACID VACCINES  
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines (NAVs) comprising polynucleotide molecules encoding one or more...
US20190008948 NUCLEIC ACID VACCINES  
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines (NAVs) comprising polynucleotide molecules encoding one or more...
10172935 Vaccination in newborns and infants  
The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age...
US20190000959 NUCLEIC ACID VACCINES  
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines (NAVs) comprising polynucleotide molecules encoding one or more...
US20190000952 IMMUNOGENIC COMPOSITIONS FOR USE IN PNEUMOCOCCAL VACCINES  
An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 10A and 39, while limiting the number...
US20180371030 NEISSERIA MENINGITIDIS COMPOSITION AND METHODS THEREOF  
In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B subfamily A A12 polypeptide. In another aspect, the invention relates to an...
US20180360956 Vaccine  
The invention provides a pro-resolving mediator for use in the reduction of reactogenicity induced by administration of a vaccine or immunogenic composition comprising at least an antigen, and...
10150797 Respiratory syncytial virus (RSV) vaccine  
The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment,...
10149901 Influenza vaccines with reduced amounts of squalene  
Influenza vaccines include hemagglutinin from at least one influenza A virus strain and at least one influenza B virus strain. They also include an oil-in-water emulsion adjuvant with submicron...
US20180339061 ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS  
Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use...
US20180339037 OIL-IN-WATER EMULSION INFLUENZA VACCINE  
The present invention provides an immunogenic influenza composition in a dose volume suitable for human use, comprising an influenza virus antigen or antigenic preparation thereof and an adjuvant...
10137192 Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections  
This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37° C. that can be produced at remarkably...
US20180334515 METHODS FOR MAKING SACCHARIDE-PROTEIN GLYCOCONJUGATES  
The invention provides a process for the reductive amination of a carbonyl group at the reducing terminus of a polysaccharide, wherein the reductive amination is carried out at a pH between 4 and...
US20180333479 INFLUENZA VIRUS VACCINES AND USES THEREOF  
Provided herein are chimeric influenza hemagglutinin (HA) polypeptides, compositions comprising the same, vaccines comprising the same, and methods of their use.
US20180333406 BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF  
The present invention generally relates to compositions comprising benzonapthyridine small molecule immune potentiators (SMIPs) that are capable of stimulating or modulating an immune response in...
US20180327460 MUTANT FRAGMENTS OF OSPA AND METHODS AND USES RELATING THERETO  
The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use...
10124051 Meningococcus serogroup X conjugate  
The invention provides a conjugate of a Neisseria meningitidis serogroup X capsular polysaccharide and a carrier molecule. The conjugate is typically made by (a) oxidizing a primary hydroxyl group...
10124050 Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof  
The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic...
US20180318410 COMBINATION VACCINES WITH SEROGROUP B MENINGOCOCCUS AND D/T/P  
Serogroup B meningococcus antigens can successfully be combined with diphtheria, tetanus and pertussis toxoids (“DTP”) to provide effective combination vaccines for protecting against multiple...
US20180318407 PCSK9 VACCINE  
The present invention relates to the provision of novel immunogens comprising an antigenic PCSK9 peptide linked to an immunogenic carrier for the prevention, treatment or alleviation of...
10117933 Antibodies against Clostridium difficile  
Compositions and methods for the treatment or prevention of Clostridium difficile infection in a subject are provided. The compositions comprise antibodies to Clostridium difficile toxin B. The...

« search again